Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B8a395116e3e8987b75395feb6653ad9e> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B8a395116e3e8987b75395feb6653ad9e NCIT_P378 "NCI" @default.
- B8a395116e3e8987b75395feb6653ad9e type Axiom @default.
- B8a395116e3e8987b75395feb6653ad9e annotatedProperty IAO_0000115 @default.
- B8a395116e3e8987b75395feb6653ad9e annotatedSource NCIT_C71704 @default.
- B8a395116e3e8987b75395feb6653ad9e annotatedTarget "An orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Voxtalisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cell populations. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion in response to nutrient and energy deprivation. Accordingly, this agent maybe more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone." @default.